_id
690da956ccc777a4e85d0842
Ticker
ACTU
Name
Actuate Therapeutics, Inc. Common stock
Exchange
NASDAQ
Address
1751 River Run, Fort Worth, TX, United States, 76107
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://actuatetherapeutics.com
Description
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Last Close
5.52
Volume
30089
Current Price
5.75
Change
0.19
Last Updated
2026-01-21T20:48:22.362Z
Image
data:image/webp;base64,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
Ipo Date
2024-08-13T00:00:00.000Z
Market Cap
136670768
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
4.6667
Target Price
26.75
Strong Buy
2
Buy
1
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
5472378
Operating Income
-5472378
Interest Expense
5063
Pretax Income
-5407470
Net Income
-5407470
Eps
-0.2527449799520588
Dividends Per Share
-
Shares Outstanding
23243328
Income Tax Expense
-
EBITDA
-5402407
Operating Margin
-
Total Other Income Expense Net
64908
Cash
16924763
Short Term Investments
-
Receivables
-
Inventories
-
Total Current Assets
17444000
Property Plant Equipment
-
Total Assets
17713933
Payables
1245375
Short Term Debt
-
Long Term Debt
-
Total Liabilities
6777653
Equity
10936280
Bs_currency_symbol
USD
Depreciation
-
Change In Working Capital
-3075916
Cash From Operations
-6677709
Capital Expenditures
3
Cash From Investing
-
Cash From Financing
17109816
Net Change In Cash
10432107
Cf_currency_symbol
USD
PE
-
PB
11.248893476575217
ROE
-49.44524097773649
ROA
-30.526648147534484
FCF
-6677712
Fcf Percent
-
Piotroski FScore
1
Health Score
23
Deep Value Investing Score
3.5
Defensive Investing Score
6.5
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
1.5
Growth Investing Score
0.5
Momentum Investing Score
3
Net Net Investing Score
2.5
Quality Investing Score
2.5
Value Investing Score
4.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
5472378
Quarters > 0 > income Statement > operating Income
-5472378
Quarters > 0 > income Statement > interest Expense
5063
Quarters > 0 > income Statement > pretax Income
-5407470
Quarters > 0 > income Statement > net Income
-5407470
Quarters > 0 > income Statement > eps
-0.2527449799520588
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
21394965
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-5402407
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
64908
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
16924763
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
17444000
Quarters > 0 > balance Sheet > property Plant Equipment
-
Quarters > 0 > balance Sheet > total Assets
17713933
Quarters > 0 > balance Sheet > payables
1245375
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
6777653
Quarters > 0 > balance Sheet > equity
10936280
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-5407470
Quarters > 0 > cash Flow > depreciation
-
Quarters > 0 > cash Flow > change In Working Capital
-3075916
Quarters > 0 > cash Flow > cash From Operations
-6677709
Quarters > 0 > cash Flow > capital Expenditures
3
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
17109816
Quarters > 0 > cash Flow > net Change In Cash
10432107
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.2527449799520588
Quarters > 0 > ratios > PB
11.248893476575217
Quarters > 0 > ratios > ROE
-49.44524097773649
Quarters > 0 > ratios > ROA
-30.526648147534484
Quarters > 0 > ratios > FCF
-6677712
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
23
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
-
Quarters > 1 > income Statement > operating Expenses
5968877
Quarters > 1 > income Statement > operating Income
-5968877
Quarters > 1 > income Statement > interest Expense
5062
Quarters > 1 > income Statement > pretax Income
-5949405
Quarters > 1 > income Statement > net Income
-5949405
Quarters > 1 > income Statement > eps
-0.30282302550457524
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
19646475
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-5944343
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
19472
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
6492656
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
6688559
Quarters > 1 > balance Sheet > property Plant Equipment
-
Quarters > 1 > balance Sheet > total Assets
6968901
Quarters > 1 > balance Sheet > payables
3171015
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
9622605
Quarters > 1 > balance Sheet > equity
-2653704
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-5949405
Quarters > 1 > cash Flow > depreciation
-
Quarters > 1 > cash Flow > change In Working Capital
191311
Quarters > 1 > cash Flow > cash From Operations
-4348987
Quarters > 1 > cash Flow > capital Expenditures
3
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
6952238
Quarters > 1 > cash Flow > net Change In Cash
2603251
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.30282302550457524
Quarters > 1 > ratios > PB
-42.569642752168285
Quarters > 1 > ratios > ROE
224.19248718018287
Quarters > 1 > ratios > ROA
-85.3707779748916
Quarters > 1 > ratios > FCF
-4348990
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
30
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
6365584
Quarters > 2 > income Statement > operating Income
-6365584
Quarters > 2 > income Statement > interest Expense
5063
Quarters > 2 > income Statement > pretax Income
-6317024
Quarters > 2 > income Statement > net Income
-6317024
Quarters > 2 > income Statement > eps
-0.3239876475883271
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
19497731
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-6311961
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
48560
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
3889405
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
4248564
Quarters > 2 > balance Sheet > property Plant Equipment
-
Quarters > 2 > balance Sheet > total Assets
4483039
Quarters > 2 > balance Sheet > payables
2644349
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
9570776
Quarters > 2 > balance Sheet > equity
-5087737
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-6317024
Quarters > 2 > cash Flow > depreciation
6365584
Quarters > 2 > cash Flow > change In Working Capital
568120
Quarters > 2 > cash Flow > cash From Operations
-4618740
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
-133477
Quarters > 2 > cash Flow > net Change In Cash
-4752217
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.3239876475883271
Quarters > 2 > ratios > PB
-22.035721038646457
Quarters > 2 > ratios > ROE
124.16176386475952
Quarters > 2 > ratios > ROA
-140.90941435039937
Quarters > 2 > ratios > FCF
-4618740
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
30
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
6559128
Quarters > 3 > income Statement > operating Income
-6559128
Quarters > 3 > income Statement > interest Expense
5076
Quarters > 3 > income Statement > pretax Income
-6446089
Quarters > 3 > income Statement > net Income
-6446089
Quarters > 3 > income Statement > eps
-0.3303199272916743
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
19514684
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-6322898
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
113039
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
8641622
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
9207900
Quarters > 3 > balance Sheet > property Plant Equipment
-
Quarters > 3 > balance Sheet > total Assets
9318448
Quarters > 3 > balance Sheet > payables
1921189
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
9214262
Quarters > 3 > balance Sheet > equity
104186
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-6446089
Quarters > 3 > cash Flow > depreciation
118115
Quarters > 3 > cash Flow > change In Working Capital
477011
Quarters > 3 > cash Flow > cash From Operations
-4772415
Quarters > 3 > cash Flow > capital Expenditures
5
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
-109412
Quarters > 3 > cash Flow > net Change In Cash
-4881827
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.3303199272916743
Quarters > 3 > ratios > PB
1077.010663620832
Quarters > 3 > ratios > ROE
-6187.097114775498
Quarters > 3 > ratios > ROA
-69.17556442875465
Quarters > 3 > ratios > FCF
-4772420
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
8
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
-
Annuals > 0 > income Statement > gross Profit
-
Annuals > 0 > income Statement > operating Expenses
25160734
Annuals > 0 > income Statement > operating Income
-25160734
Annuals > 0 > income Statement > interest Expense
18717
Annuals > 0 > income Statement > pretax Income
-27284528
Annuals > 0 > income Statement > net Income
-27285328
Annuals > 0 > income Statement > eps
-1.3981947132733483
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
19514684
Annuals > 0 > income Statement > income Tax Expense
800
Annuals > 0 > income Statement > EBITDA
-25160734
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
-2123794
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
8641622
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
9207900
Annuals > 0 > balance Sheet > property Plant Equipment
-
Annuals > 0 > balance Sheet > total Assets
9318448
Annuals > 0 > balance Sheet > payables
1921189
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
9214262
Annuals > 0 > balance Sheet > equity
104186
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-27285328
Annuals > 0 > cash Flow > depreciation
2143311
Annuals > 0 > cash Flow > change In Working Capital
1100076
Annuals > 0 > cash Flow > cash From Operations
-21842648
Annuals > 0 > cash Flow > capital Expenditures
0
Annuals > 0 > cash Flow > cash From Investing
-
Annuals > 0 > cash Flow > cash From Financing
27525611
Annuals > 0 > cash Flow > net Change In Cash
5682963
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-1.3981947132733483
Annuals > 0 > ratios > PB
1077.010663620832
Annuals > 0 > ratios > ROE
-26189.05419154205
Annuals > 0 > ratios > ROA
-292.80978978473667
Annuals > 0 > ratios > FCF
-21842648
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
8
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
-
Annuals > 1 > income Statement > gross Profit
-
Annuals > 1 > income Statement > operating Expenses
24973829
Annuals > 1 > income Statement > operating Income
-24973829
Annuals > 1 > income Statement > interest Expense
43641
Annuals > 1 > income Statement > pretax Income
-24744620
Annuals > 1 > income Statement > net Income
-24744620
Annuals > 1 > income Statement > eps
-1.6459400530713235
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
15033731
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-24428129
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
229209
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
2958659
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
-
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
2995566
Annuals > 1 > balance Sheet > property Plant Equipment
-
Annuals > 1 > balance Sheet > total Assets
2995566
Annuals > 1 > balance Sheet > payables
3421840
Annuals > 1 > balance Sheet > short Term Debt
-
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
102622079
Annuals > 1 > balance Sheet > equity
-99626513
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-24744620
Annuals > 1 > cash Flow > depreciation
272850
Annuals > 1 > cash Flow > change In Working Capital
2572451
Annuals > 1 > cash Flow > cash From Operations
-21625167
Annuals > 1 > cash Flow > capital Expenditures
0
Annuals > 1 > cash Flow > cash From Investing
-
Annuals > 1 > cash Flow > cash From Financing
4134516
Annuals > 1 > cash Flow > net Change In Cash
-17490651
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-1.6459400530713235
Annuals > 1 > ratios > PB
-0.8676802052682503
Annuals > 1 > ratios > ROE
24.837384401881053
Annuals > 1 > ratios > ROA
-826.0415560865627
Annuals > 1 > ratios > FCF
-21625167
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
-
Annuals > 2 > income Statement > operating Expenses
20206807
Annuals > 2 > income Statement > operating Income
-20206807
Annuals > 2 > income Statement > interest Expense
16200
Annuals > 2 > income Statement > pretax Income
-20159401
Annuals > 2 > income Statement > net Income
-20159401
Annuals > 2 > income Statement > eps
-1.3409446397570903
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
15033731
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-20079595
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
47406
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
20449310
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
-
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
20483056
Annuals > 2 > balance Sheet > property Plant Equipment
-
Annuals > 2 > balance Sheet > total Assets
20483056
Annuals > 2 > balance Sheet > payables
2130847
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
5650737
Annuals > 2 > balance Sheet > equity
14832319
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-20159400
Annuals > 2 > cash Flow > depreciation
63606
Annuals > 2 > cash Flow > change In Working Capital
1731621
Annuals > 2 > cash Flow > cash From Operations
-17794093
Annuals > 2 > cash Flow > capital Expenditures
0
Annuals > 2 > cash Flow > cash From Investing
-
Annuals > 2 > cash Flow > cash From Financing
19255569
Annuals > 2 > cash Flow > net Change In Cash
1461476
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-1.3409446397570903
Annuals > 2 > ratios > PB
5.828080777523731
Annuals > 2 > ratios > ROE
-135.91536832507444
Annuals > 2 > ratios > ROA
-98.41988910248548
Annuals > 2 > ratios > FCF
-17794093
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
29
Valuation > metrics > PE
-0.2527449799520588
Valuation > metrics > PB
11.248893476575217
Valuation > final Score
20
Valuation > verdict
275.0% Overvalued
Profitability > metrics > ROE
-49.44524097773649
Profitability > metrics > ROA
-30.99902545287778
Profitability > metrics > Net Margin
-
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.6197402590277499
Risk > metrics > Interest Coverage
-1080.8568042662453
Risk > final Score
-4275
Risk > verdict
High
Liquidity > metrics > Current Ratio
14.007025996185888
Liquidity > metrics > Quick Ratio
14.007025996185888
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
20
Prev Profitabilities > 0
40
Prev Profitabilities > 1
40
Prev Profitabilities > 2
0
Prev Risks > 0
-4687
Prev Risks > 1
-4999
Prev Risks > 2
-5163
Prev Liquidities > 0
100
Prev Liquidities > 1
90
Prev Liquidities > 2
100
Updated At
2026-01-21T20:48:23.051Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-31
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-0.24
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-09-30
Earnings History > 1 > report Date
2025-11-13
Earnings History > 1 > date
2025-09-30
Earnings History > 1 > before After Market
AfterMarket
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.25
Earnings History > 1 > eps Estimate
-0.28
Earnings History > 1 > eps Difference
0.03
Earnings History > 1 > surprise Percent
10.7143
Earnings History > 2 > period
2025-06-30
Earnings History > 2 > report Date
2025-08-14
Earnings History > 2 > date
2025-06-30
Earnings History > 2 > before After Market
AfterMarket
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.3
Earnings History > 2 > eps Estimate
-0.31
Earnings History > 2 > eps Difference
0.01
Earnings History > 2 > surprise Percent
3.2258
Earnings History > 3 > period
2025-03-31
Earnings History > 3 > report Date
2025-05-15
Earnings History > 3 > date
2025-03-31
Earnings History > 3 > before After Market
AfterMarket
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-0.32
Earnings History > 3 > eps Estimate
-0.3
Earnings History > 3 > eps Difference
-0.02
Earnings History > 3 > surprise Percent
-6.6667
Earnings History > 4 > period
2024-12-31
Earnings History > 4 > report Date
2025-02-26
Earnings History > 4 > date
2024-12-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
-0.33
Earnings History > 4 > eps Estimate
-0.29
Earnings History > 4 > eps Difference
-0.04
Earnings History > 4 > surprise Percent
-13.7931
Earnings History > 5 > period
2024-09-30
Earnings History > 5 > report Date
2024-11-27
Earnings History > 5 > date
2024-09-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-0.55
Earnings History > 5 > eps Estimate
-
Earnings History > 5 > eps Difference
0
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2024-06-30
Earnings History > 6 > report Date
2024-08-28
Earnings History > 6 > date
2024-06-30
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-4.2
Earnings History > 6 > eps Estimate
-
Earnings History > 6 > eps Difference
0
Earnings History > 6 > surprise Percent
-
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AActuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers marketscreener.com
Read more →Energy Stocks And Industry News: Oil, Gas, Solar, Coal And Nuclear Energy Investor's Business Daily
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$26.75
Analyst Picks
Strong Buy
2
Buy
1
Hold
0
Sell
0
Strong Sell
0
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Medium
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Actuate Therapeutics, Inc. Common stock
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
-0.24
Date
2025-09-30
EPS Actual
-0.25
EPS Estimate
-0.28
EPS Difference
0.03
Surprise Percent
10.7143%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.